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EDITORIAL: SODIUM-HYDROGEN EXCHANGE INHIBITION--A SUPERIOR CARDIOPROTECTIVE 
STRATEGY 
Morris Karmazyn, PhD* 
T he heart cell possesses precisely regulated mech- anisms for maintaining intracellular pH at phys- 
iologic values, particularly during pathologic ondi- 
tions such as myocardial ischemia. Among these 
processes, the sodium-hydrogen xchanger (NHE) 
represents a major mode of proton extrusion after 
acidosis; stimulation of the exchanger is particularly 
strong at the time of reperfusion although it is also 
active during ischemia. The idiosyncrasies ofnature, 
however, are often suggestive of much more com- 
plex consequences of homeostatic processes than 
are first apparent, and NHE activation is no excep- 
tion. Accordingly, it has been proposed 1 that stim- 
ulation of the exchanger, despite its necessity for 
intracellular pH (pHi) restoration after acidosis, 
may contribute to myocardial injury. The concomi- 
tant influx of sodium ions creates an osmotic imbal- 
ance but can also result in elevations in intracellular 
calcium concentrations through sodium-calcium ex- 
change, thus producing potentially deleterious cal- 
cium overloading conditions. Therefore, the anti- 
port is a paradoxic phenomenon because it is a 
major mechanism for restoration of pH i after isch- 
emia. As a consequence, however, cell injury occurs. 
In this issue of the Journal, Koike and coworkers 2 
report the beneficial effects of sodium-hydrogen 
exchange inhibition in a rabbit model of global 
normothermic ischemia followed by reperfusion. 
Using standard recording techniques coupled with 
phosphorus 31-nuclear magnetic resonance spec- 
troscopy, they convincingly demonstrate hat inhibi- 
tion of the antiport reduces both ischemia- and 
reperfusion-induced mechanical dysfunction. Of 
further importance in this study is that the beneficial 
From the Department of Pharmacology and Toxicology, Univer- 
sity of Western Ontario Faculty of Medicine, Medical Sci- 
ences Building, London, Ontario N6A 5C1, Canada. 
Requested for publication April 3, 1996; received for publication 
May 6, 1996. 
*Career Investigator of The Heart and Stroke Foundation of 
Ontario. 
J Thorac Cardiovasc Surg 1996;112:776-7 
Copyright © 1996 by Mosby-Year Book, Inc. 
0022-5223/96 $5.00 + 0 12/1/74705 
influence on function was associated with expected 
effects of NHE inhibition--increased acidosis dur- 
ing ischemia and depressed recovery from the aci- 
dosis during early reperfusion. Both of these effects 
reflect diminished proton extrusion thereby render- 
ing acid neutralization dependent on other pH- 
regulatory systems. As this study also suggests, and 
as alluded to by the authors, moderate intracellular 
acidification as a consequence of NHE activity may 
produce other beneficial actions i  the ischemic and 
reperfused myocardium as a result of the inhibition 
of calcium influx by direct inhibitory effects of 
protons on the calcium channel. The authors also 
report that the protection afforded by NHE inhibi- 
tion can be dissociated from preservation of myo- 
cardial stores of high-energy phosphates, a finding 
in agreement with other but not all studies (re- 
viewed in Karmazyn and Moffat 3 and Karmazyn4). 
Therefore this aspect of myocardial protection as- 
sociated with NHE requires further studies. 
The study by Koike and associates 2 adds further 
strength to the concept hat the myocardial NHE 
represents an effective target for pharmacologic 
intervention for the protection of the ischemic and 
reperfused myocardium. This offers the prospect for 
novel and effective strategies for myocardial protec- 
tion which, for reasons outlined herein, may be 
superior to current approaches. From the pharma- 
cologic perspective, an abundance of drugs are 
available that are relatively potent and specific in 
their ability to inhibit NHE. Most of them are 
represented by analogs of amiloride, a potassium- 
sparing diuretic, such as dimethyl amiloride, which 
was used by Koike's group. 2 These drugs are not 
without nonspecific effects, however, particularly 
when used in higher amounts. Novel agents uch as 
HOE 642 and HOE 694, which are unrelated to the 
amiloride series, offer perhaps more promise as 
effective and specific NHE inhibitors. 5'6 HOE 642 in 
particular is conceptually a highly attractive poten- 
tial therapeutic agent because it is specific to the 
major NHE isoform (termed NHE-1) in the heart. 
(At least five different NHE subtypes have been 
identified, which differ in structure, are generally 
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tissue and cell specific, and possess varied sensitivi- 
ties to inhibition by pharmacologic agents.) 
Does inhibition of NHE offer a superior approach 
to cardiac protection and preservation when as- 
sessed in relation to other cardioprotective agents? 
Current evidence is strongly supportive of this con- 
cept for at least the following four reasons (reviewed 
in detail in references 3 and 4): (1) The protective 
actions of NHE inhibitors have been uniformly 
demonstrated, with few, if any, studies failing to 
show protection. (2) Protection with NHE inhibitors 
has been observed in a variety of experimental 
models, animal species as well as modes of injury 
including both cell necrosis and myocardial stun- 
ning. In addition to protective actions against acute 
short-term myocardial ischemia, NHE inhibition 
also results in marked myocardial preservation i  
hearts subjected to prolonged (12-hour) hypother- 
mic storage. 7 (3) An additional salutary effect of 
NHE inhibition may also involve attenuation ofboth 
platelet and neutrophil activation--two factors that 
are important mediators of cardiac injury--in addi- 
tion to the direct effects of NHE inhibition on the 
cardiac cell. (4) Potential toxic effects of specific 
NHE inhibitors are likely to be minimal because of 
low activity of the antiport under physiologic ondi- 
tions thus potentially precluding significant effects 
on normal homeostatic processes. Moreover, the 
development of selective tissue-specific NHE inhib- 
itors further diminishes potential for untoward ef- 
fects. Despite the need for further research, partic- 
ularly with respect to defining precise mechanism of 
action, Koike and coworkers 2 further remind us of 
the potential promise of NHE inhibitors as thera- 
peutic agents, particularly with respect o effective 
adjuncts in cardioplegic solutions for surgery as well 
as heart preservation for transplantation. 8 
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